The company’s PLacental eXpanded cells have potential as a cell therapy product for muscle and tendon regeneration that can be used to enhance repair after rotator cuff surgery.
There are currently no U.S. Food and Drug Administration-approved therapies using engineered cells for rotator cuff injuries.
More Articles on Devices:
5 Key Results: LDR’s Mobi-C Artificial Disc Replacement vs. ACDF
FDA Clears AccelSPINE’s Next Generation Minimally Invasive Spine System
Global Medical Device Market to Grow at 6.2% Annually Until 2018
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
